Peakdale Molecular Limited Announces Innovative On-Site Research Collaboration With Pfizer Sandwich Laboratories

News provided by

Peakdale Molecular

Feb 01, 2010, 06:54 ET

CHAPEL-EN-LE-FRITH, England, February 1 /PRNewswire/ -- Peakdale Molecular Limited ("Peakdale"), a leading research Services Company headquartered in the UK, announced today that it has entered into an agreement with Pfizer Limited. Peakdale Molecular, through its wholly owned subsidiary Peakdale Chemistry Services Ltd, will supply custom synthetic chemistry services to Pfizer on-site at the company's laboratories in Sandwich, UK. This will involve building a team of more than 50 synthetic chemists at the Pfizer Research site in Kent, supplementing the main Peakdale facility in Derbyshire, which employs 90 synthetic chemists.

This facility will not only provide on-site chemistry resources for Pfizer, but also provide a resource for other developing companies in the vicinity. The presence of a world-class chemistry development facility will add to the attraction of the Sandwich site as an innovation hub for the region.

Dr Tony Wood, Vice President, Pfizer World-Wide Medicinal Chemistry said: "Synthetic organic chemistry sits at the centre of drug discovery. This collaboration will allow Pfizer to continue to develop a strong community of experienced synthetic chemists within its facilities and enhance the overall culture of synthetic chemistry at the Sandwich site."

"The positioning of Peakdale chemists close to the core of our research operations gives a unique opportunity in this outsourced space," said David Roblin, Sandwich Head of Research and Site Director of Pfizer Sandwich Laboratories. "In addition, this move begins to enhance the utilisation of the real estate assets we have at Sandwich. I hope this is just the first example we will see in this vein."

"This is a great opportunity for Peakdale to contribute to Pfizer's success as the pharmaceutical industry seeks to become more efficient and responsive to the rapidly changing environment of drug discovery," said Ray Fisher, PhD, Founder and CEO, Peakdale Molecular Limited. "We are extremely pleased that Pfizer has chosen us to promote this new initiative and see this model as one way to bring the entrepreneurial spirit of smaller companies to synergise with the expertise and know-how of an established world leader."

    For further information, please contact:

    Elizabeth Power +1(860)732-4987
    Pfizer Media & Publications Group

    Mike Wort / Anna Dunphy +44(0)207-861-3838
    De Facto Communications

    Ray Fisher +44(0)1298-816-702
    CEO
    Peakdale

SOURCE Peakdale Molecular

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED